Summary
Introduction
Pathological evidence for microangiopathy in human diabetic using careful quantitative techniques, have reported reductions in nerve blood flow as early as 1 week following polyneuropathy is well described. Several investigators have described the following changes: closed capillaries (Dyck the onset of experimental streptozotocin-induced diabetes in rats (Cameron et al., 1991b ). An early fall in local blood et al., 1985) ; microvascular thrombosis (Williams et al., 1980; Timperley et al., 1985) ; basement membrane thickening flow of experimental diabetes has also been reported by several other groups, but some of these studies have had (Malik et al., 1989; Giannini and Dyck 1994) ; endothelial cell reduplication (Williams et al., 1980; methodological flaws. These flaws have included using insufficient numbers of laser Doppler flowmetry measure-1985; Giannini and Dyck 1994) ; and multifocal loss of myelinated fibres (Dyck et al., 1986a, b; Johnson et al., ments, lack of temperature control of the preparation, or inappropriately large hydrogen microelectrodes (Yasuda 1986) . Despite this evidence, it is controversial whether microangiopathy is the cause of early human diabetic et al., 1989; Hotta et al., 1992 Hotta et al., , 1995 Kappelle et al., 1993; Stevens et al., 1993 Stevens et al., , 1994 Stevens and Tomlinson 1995 ; polyneuropathy because these changes occur in already established neuropathy. This problem has been addressed, but Wright and Nukada 1994) . In other studies investigators have been unable to identify reductions in nerve blood flow in experinot resolved in animal models of diabetes. Some investigators, mental diabetes or have identified increased nerve blood flow were included in the vasculitis group only if changes of vasculitis were identified in the biopsy. (Pugliese et al., 1989; Zochodne and Ho, 1992a, b; Zochodne et al., , 1996a Tilton et al., 1993 Tilton et al., , 1995 . Technical differences in the preparation and methodology may account for Sural nerve blood flow these differences in findings and are reviewed in depth elseSural nerve blood flow was measured using a 1.0-mmwhere . diameter fibre-optic probe connected to a laser Doppler In this study, we measured human sural nerve blood flow flowmeter (Perimed PF3; Smithtown, NY, USA) sensitive to pior to nerve biopsy in a group of 26 patients being entered in local red blood cell flux. Individual red blood cell flux a multicentre clinical trial of mild diabetic polyneuropathy.
measurements do not provide quantitative blood flow values The measurements were made using a laser Doppler probe in ml/100g/min since the signal is determined by both local sensitive to local red blood cell flux under controlled conditions red blood cell velocity and the numbers of moving red blood that have provided, in prior animal work, consistent flux cells from which the reflected laser signal is acquired. To signals with acceptable variability (Takeuchi and Low 1987;  provide quantitative measurements in relative flux units, Kalichman and Lalonde 1991; Zochodne et al., 1995) . The however, multiple individual signals can be recorded to results were compared with sural nerve blood flow measureprovide a mean sural nerve blood flow value. Under carefully ments in 22 patients who underwent diagnostic sural nerve controlled conditions, this technique provides reproducible biopsy that led to a variety of pathological diagnoses and served data that correlates, in experimental work, with measurements as 'disease controls'. made using other quantitative techniques, such as hydrogen clearance polarography (Takeuchi and Low, 1987; Kalicham and Lalonde, 1991; Zochodne et al., 1995) . We used several
Methods
approaches to control our recording conditions in order to provide consistent quantitative results: (i) measurements were
Patients with mild diabetic polyneuropathy
made with the probe just at the epineurial surface of the Twenty-six patients with diabetic polyneuropathy were local nerve with care taken not to compress surface vessels or participants in a multicentre trial (Alcar multicentre clinical stretch the nerve with excessive retraction; (ii) the probe was trial; acetyl-L-carnitine; Hoffmann-La Roche). The protocols routinely positioned at~90°to the surface of the nerve for the drug trial and for additional sural nerve blood flow and it was held in place during the measurement using a measurements prior to biopsy were reviewed and approved by micromanipulator; (iii) measurements were made at 10 the University of Calgary conjoint ethics committee, and all different sites along the exposed nerve and the final sural patients gave informed consent to participate. The protocol nerve blood flow measurement was taken as the mean of required an initial sural nerve biopsy, randomly assigned as these values; (iv) at each site, the probe was left in place right or left, followed 1 year later (after double-blinded therapy) until the signal had stabilized before a recording was made; by a contralateral sural nerve biopsy. The patients selected for (v) the ambient room lights in the operating theatre were the trial were required to fulfill modified San Antonio criteria turned off during the recordings; (vi) the same investigator (Consensus Panel, 1988) for the diagnosis of diabetic poly-(M.T.) positioned the probe and set up the recordings in neuropathy (in brief these were the presence in an individual all patients. patient of two of four criteria among clinical symptoms of Recordings were made immediately after the skin over polyneuropathy, clinical signs, reduced vibration perception the sural nerve was incised and the nerve was exposed threshold, abnormal sural or peroneal nerve conduction).
leaving the nerve in its bed, in order to minimize trauma Patients had clinically stable diabetes and no evidence of to it. Incisions and later resections of the nerve were made confounding systemic disorders (more detailed inclusion/ at the level of the lateral malleolus and taken proximally exclusion criteria for the trial are available from the corresfor 6-12 cm. The nerve was not dissected prior to sural ponding author); having a relatively mild disease, with a nerve blood flow measurements and care was taken to recordable sural potential of Ͼ1.0 µV in amplitude, was one apply local anaesthesia (lidocaine 2.0%) to the skin, but of the inclusion criteria. At the completion of the trial, analysis not the epineurial surface of the sural nerve prior to of results did not demonstrate that acetyl-L-carnitine was of biopsy. Except in one patient described below, epinephrine benefit in diabetic polyneuropathy (Hoffmann-La Roche;
was not used over the nerve or for skin anaesthesia. Skin personal communication).
and muscle bleeding was controlled by ligation and bipolar cautery, but no nerve vessels had significant bleeding and none required ligation or coagulation.
Patients with other polyneuropathies
Twenty-two patients with various polyneuropathies (Table 1) Electrophysiology, nerve morphometry and were studied prior to diagnostic sural nerve biopsy. These patients also gave informed consent for the sural nerve blood statistical analysis flow measurement. Final diagnoses were established using Sural nerve conduction recordings were made using standardized surface stimulating and recording electrodes. clinical, electrophysiological and pathological criteria. Patients ; IDDM ϭ insulin dependent diabetes mellitus; NIDDM ϭ non-insulin dependent diabetes mellitus; CIDP ϭ chronic inflammatory demyelinating polyneuropathy; GBS ϭ Guillain-Barré syndrome; PNS ϭ peripheral nervous system; SLE ϭ systemic lupus erythematosus.
The recording electrode was placed just behind the lateral malleolus and stimulation carried out 120-150 mm proximally. Nerve morphometry was completed at the University of Michigan, under agreement with Hoffmann-LaRoche. Results reported here were released with the formal permission of Hoffmann-LaRoche. Methods were previously reported (Sima et al., 1988) .
The data were analysed using means and standard errors, Student's t tests that were both paired and unpaired (two-tailed; null hypothesis rejected for P ഛ 0.05) and linear regression analysis.
Results
Patient information is given in Table 1 . Sural nerve blood flow in patients with mild diabetic neuropathy measured slightly higher (though not statistically significant) than that in patients with other polyneuropathies, excluding those with vasculitis, epinephrine application or lumbosacral plexopathy (Fig. 1) . Mean sural nerve blood flow (ϮSE) in patients with mild Table 1 . Sural below the mean value in patients with other, non-vasculitic neuropathies, but was comparable with the sural nerve blood nerve blood flow within these diagnostic categories did not appear to vary with the specific diagnosis. In three patients flow result in two of the patients with vasculitis (Fig. 1) . One additional diabetic patient, not involved in the clinical with vasculitic polyneuropathy, mean sural nerve blood flow was lower (102 Ϯ 12 perfusion units) than values in either trial, underwent a diagnostic sural nerve biopsy because of a rapidly progressive and disabling polyneuropathy. This mild diabetic polyneuropathy or in other, non-vasculitic polyneuropathies (vasculitis versus other; P ϭ 0.03). In one patient had weight loss, leg pain, distal lower leg weakness, sensory loss to the knees and also evidence of bilateral patient with a cryptogenic polyneuropathy, epinephrine (1.0%) was superfused over the epineurium of the sural nerve lumbosacral plexopathy with asymmetric proximal lower limb wasting and weakness. Sural nerve blood flow (104 by the surgeon prior to the blood flow measurement. Sural nerve blood flow in this patient (85 perfusion units) was Ͼ2 SDs perfusion units) was Ͼ2 SD below the mean value of patients with mild diabetic polyneuropathy and 1.5 SD below the 0.5; P Ͻ 0.0001). There was no correlation between fibre density and sural nerve blood flow in nondiabetic subjects value of patients with other, non-vasculitic polyneuropathies. (Fig. 2) . Patients with non-insulin dependent diabetes mellitus In patients with mild diabetic polyneuropathy, sural nerve (n ϭ 20) did not have significantly different sural nerve blood flow did not correlate with the pre-biopsy sural nerve blood flow from those with insulin dependent diabetes potential amplitude, sural nerve myelinated fibre density, mellitus (n ϭ 6) (160 Ϯ 4 non-insulin dependent diabetes haemoglobin A 1C , duration of diabetes, or age of the patient mellitus versus 176 Ϯ 13 insulin dependent diabetes mellitus). (Figs 2 and 3 ). There was a highly significant correlation In 10 patients, following the 1-year duration of the clinical between sural nerve myelinated fibre density and the trial, a repeat sural nerve biopsy was obtained from the prebiopsy sural nerve potential amplitude (r ϭ 0.71, r 2 ϭ contralateral lower limb. Sural nerve blood flow values in the initial biopsied nerve (160 Ϯ 6 perfusion units) did not differ significantly from sural nerve blood flow in the second sural nerve (185 Ϯ 14 perfusion units) biopsied from the same patient: there was an overall, but not statistically significant trend toward increased blood flow after 1 year. Acetyl-L-carnitine had no influence on these changes. Figure  3 illustrates the changes in sural nerve blood flow, fibre density and sural nerve potential amplitude in 10 patients, who had two measurements, one in each sural nerve 1 year apart. The sural nerve potential amplitude was similar on each side, after 1 year (3.9 Ϯ 0.8 µV in the first year; 4.5 Ϯ 1.0 µV in the second year) and there was a trend, not statistically significant, toward a decline in myelinated fibre density (3614 Ϯ 695/mm 2 in the first year; 3230 Ϯ 665/mm 2 in the second year). 
Fig. 3
Individual sural nerve blood-flow measurements in 10 diabetic patients who were studied twice, 1 year apart (second biopsy was contralateral to the first). Sural nerve blood flow (RBC flux ϭ red blood cell flux) did not decline over the year. There is a correlation between fibre density and sural nerve response amplitude, but the reductions in both of these parameters did not accompany a decline in sural nerve blood flow. nerve blood flow that was similar to, if not slightly higher there is evidence for increased arteriovenous-shunt flow in some tissues in advanced diabetes, there is no evidence than, sural nerve blood flow in patients with other polyneuropathies; no single patient in this category had sural nerve that major distortions in epineurial arteriovenous-shunt flow occurs in early diabetes, as examined in our work. In blood flow that was Ͼ2 SDs below the mean value found in patients with other polyneuropathies. (ii) Patients with experimental diabetes, the presence of endoneurial ischaemia resulting in axonal conduction block was easily demonstrable vasculitis, and a single patient who was treated with epineurial epinephrine prior to resection, had reduced sural nerve blood with laser Doppler flowmetry measurement (Zochodne et al., 1996a) . Similarly, we did not observe a subset of individual flow. (iii) Sural nerve blood flow did not correlate with prebiopsy sural nerve potential amplitude, myelinated fibre low red blood cell flux readings in diabetics, remote from the influence of arteriovenous shunts. density on nerve biopsy, age of the patient, duration of the diabetes or haemoglobin A 1C value. (iv) Over the course of Finally, it might be argued that 'disease control' patients are an unsuitable group with which to compare sural nerve 1 year, sural nerve blood flow did not decline, despite a slight trend toward a lower myelinated fibre density, as blood flow from diabetes. We would argue the reverse. By studying 'disease controls' with fibre loss and no compared with the contralateral sural nerve.
Laser Doppler flowmetry may be the only practical and microangiopathy, we eliminated the possibility that fibre loss itself could have reduced sural nerve blood flow in diabetes. safe technique available for making measurements of sural nerve blood flow in humans. Laser Doppler flowmetry suffers There was no correlation between fibre density and sural nerve blood flow in diabetes or nondiabetics, indicating that disadvantages of variable individual red blood cell flux values and it does not give blood flow values in ml/100 g/min neither nonspecific fibre loss nor advancement of diabetes complications could have been linked to changes in sural but its reliability in providing quantitative data has been established in animal studies where additional blood flow nerve blood flow had we observed them. Patients with 'other neuropathies' did not have diagnoses where abnormalities measurements using other techniques (not suitable for human work) could be made for comparison. The important caveat in vasa nervorum are postulated to contribute to disease. Interestingly, a single patient with amyloid neuropathy had to this statement is the requirement for rigorously controlled measurement technique. For example, holding a laser Doppler sural nerve blood flow comparable to the values of other patients: amyloid has been considered to result in endoneurial microprobe by hand can significantly alter red blood cell flux readings, probably because of microtremor. The probe must ischaemia but our finding provided no support for such a mechanism (Kyle and Dyck, 1993) . be rigidly fixed in place at~90°to the surface of the nerve with a micromanipulator. Ambient room lights also Overall, our results do not support the contention that in human diabetic polyneuropathy, pre-existing ischaemia is the substantially influence the reading and must be turned off. Calculation of blood flow using single or small numbers of inciting factor responsible for the development of clinical and electrophysiological abnormalities. Indeed, the slight rise readings from the nerve may also increase the variability of the sural nerve blood flow value assigned. All of our in sural nerve blood flow compared with other polyneuropathies may be evidence supporting the contention recordings were made from an exposed nerve at normal operating-theatre room-temperature. In animal models, nerves that capillary hyperperfusion precedes later microvascular sclerosis in diabetes (Tooke, 1995) . After 1 year of may be warmed by bathing them in a mineral oil or saline bath positioned to prevent spillage and can be kept at a observation, there was a trend toward yet higher measurements of sural nerve blood flow. As discussed above, constant temperature with a thermistor-controlled heating lamp Ho, 1992a, b, 1994; there is histological evidence of microvascular disease that would be expected to cause ischaemia in later poly-1994, 1996a). For ethical reasons, an open surgical wound in a patient cannot be filled with bathing solutions; the nerve neuropathy. Our patient with advanced polyneuropathy and lumbosacral plexopathy with an apparent reduction of sural was kept moist only with small applications of saline. It is not practical or comfortable for patients to be positioned in nerve blood flow was within this catagory. Ischaemia has been postulated to be responsible for lumbosacral plexopathy a way that would mimic the mineral oil nerve 'pool' setup used for animal studies. Cold vasoconstriction, in animal since the original serial section study of Raff et al. (1968) of the lumbosacral plexus of a diabetic patient at autopsy. work, appears to reduce sural nerve blood flow in diabetes, a change we did not observe (Dines et al., 1995) . Since all Tesfaye et al. (1993) noted the delayed appearance of fluorescein in the sural nerves of patients with 'disabling' of our measurements were made at the same temperature and since vasoconstriction from disease was demonstrable in diabetes. Fluorescein visualization is not a recognized or quantitative approach to actual flow measurement, but the vasculitic neuropathy and epinephrine treated nerve, we believe our conclusions about the lack of influence of early findings do suggest disease of epineurial vessels in later diabetes. Ram et al. (1991) convincingly linked macrodiabetes on sural nerve blood flow are valid.
The laser Doppler flowmetry signal recorded is particularly vascular atherosclerosis in patients with diabetes to the severity of the neuropathy. Newrick et al. (1986) (Simpson, 1988) and in transit through selected capillaries. Malik et al. (1992) reported loss of capillaries in mild human the Medical Research Council of Canada and from clinical trial funding by Hoffmann-La Roche for the Alcar trial in diabetic polyneuropathy, but overall vessel lumen area was actually increased, a finding difficult to reconcile with signihuman diabetic neuropathy. Hoffmann-La Roche provided the sural myelinated fibre density data. ficant ischaemia. The development of diabetic polyneuropathy appears to result from a complex interplay of metabolic and microvascular abnormalities that cause a vicious cycle of fibre loss and ischaemia. Since sural nerve blood flow flow distal polyneuropathy (Zochodne et al., 1996b) . In our
